BioSpace News Archive

Imunon, Inc. announced that the Company will host a conference call at 11:00 a.m. ET on Monday, November 14, 2022 to discuss financial results for the third quarter ended September 30, 2022 and provide an update on its clinical development of GEN-1.

Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis (HDx) care at Kidney Week 2022, Nov. 3-6, Orlando, Florida.

Praxis Precision Medicines, Inc. announced that management will participate in the following upcoming investor conferences.

Amgen (NASDAQ:AMGN) today announced that clinical and real-world data across its broad portfolio of established treatments and pipeline assets will be presented at the annual American College of Rheumatology Convergence (ACR), taking place in Philadelphia on Nov. 10-14, 2022.

Longeveron Inc., a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets.

The global Laboratory Information Management System market size was estimated at USD 1.92 billion in 2021 and is expected to surpass around USD 3.8 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 7.88% during the forecast period 2022 to 2030.

Pear Therapeutics, Inc. announced results from a retrospective analysis to evaluate the impact of Somryst® on healthcare resource use.

Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Monday, November 14, 2022, at 8:00 AM EST to review its third quarter 2022 financial results and provide an update on the company.

Aphaia Pharma announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.

Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced interim clinical data of MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, from a Phase 1c study in RSV-naïve (seronegative) infants and young children.